The Correctors Company

We fix the underlying cause of disease.

For the diseases we go after, the biology is known: the gene, the protein and how it breaks. The hard part has been making a drug that fixes it. Correctors are small molecules that rescue the broken protein itself. We find them with our platform, testing molecules directly in human cells, at scale.

Correcting disease today

RHO-adRP. An oral corrector for inherited vision loss, now in patients.

OCT-980 · Phase 1b/2

Fabry disease. A better oral treatment, for more people.

Lead optimization

p53-mutant cancers. Switching p53 back on in the most common mutations.

Hit to lead

Why build correctors

The cause is known.
We know from day one that fixing the protein should help patients. What was missing was a way to find molecules that fix it, so we built one.
Genetic medicine, in a pill.
Correctors act on the cause like a genetic medicine, in a pill a patient can take at home.
Matched to patients early.
Before a trial begins, we know which patient variants a drug is likely to help.

Why correctors are so hard to build

Where it’s madeWhere it works
Misfolding can only be studied in a cell.Misfolded proteins have no structure to work from and only exist in living cells, so rescue has to be measured there.See how we engineer cells
BrokenRescued
One disease, hundreds of mutations.Mutations break the protein in different ways, and a viable medicine has to rescue as many of them as possible.See how we test across variants
Binds the proteinWorks in the cell
Binding isn’t correcting.A molecule can bind the protein and still leave it broken. Only the cell shows which molecules restore function.See how we test for rescue

How we test molecules in human cells, at scale

Our platform runs as a lab-in-the-loop: cells that show whether a molecule works, chemistry fast enough to feed them, and robots that can run it all around the clock.

  1. Our biology. Human cells that read out disease mechanisms

    We engineer human cells to report on the mechanism that causes disease, such as whether a protein reaches the cell surface. Different mutations to the same protein can affect that mechanism in different ways, so each gets its own barcoded cell line.

    How our cells report rescue

    An engineered human cellA molecule fixes the proteinThe cell reads it outOne barcoded line per mutationOne well, one moleculeRescue, per mutation

  2. Our chemistry. 30,000–50,000 new molecules a week

    We turn each promising hit into thousands of analogs, made in nanoliter drops. They go straight onto our cells without being purified first, a direct‑to‑biology approach.

    How we make molecules at this scale

    One hitA library of fragmentsA plate of new molecules

  3. Our automation. Up to 500,000 tests a week

    Hypatia, our robotic system, moves plates between instruments on a magnetic rail, and our scheduling software keeps it running at all hours. Data pipelines turn every readout into results our scientists and models use and learn from.

    Meet Hypatia

    Hypatia, our robotic system, at work

We make the data our models learn from

Every week, data from tens of thousands of molecules tested in billions of cells retrain our models and guide what we make next.

Then the loop runs again. Every molecule is tested the same way, at several doses and across patient variants, so each round adds to one consistent body of data. Take a standard safety test for PXR, a liver protein behind many drug interactions: the published record held about 600 measurements, scattered across 148 papers. We generated about 11,000 in a single assay.

What AI is changing at Octant

Each week, data from our cells train our models, which evolve a new set of molecules to make and test. Round by round, the best go on toward medicines.

Taking correctors to patients

In our retinitis pigmentosa program, we made and tested more than 250,000 molecules on our platform. The result is OCT-980, our investigational oral corrector for RHO-adRP, now in a Phase 1b/2 study.

See where each program stands, from discovery to the clinic.

Programs & Pipeline